• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

制作有效流感疫苗的挑战。

Challenges of Making Effective Influenza Vaccines.

机构信息

Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA; email:

出版信息

Annu Rev Virol. 2020 Sep 29;7(1):495-512. doi: 10.1146/annurev-virology-010320-044746. Epub 2020 May 11.

DOI:10.1146/annurev-virology-010320-044746
PMID:32392457
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7529958/
Abstract

Seasonal influenza vaccines prevent influenza-related illnesses, hospitalizations, and deaths. However, these vaccines are not as effective as other viral vaccines, and there is clearly room for improvement. Here, we review the history of seasonal influenza vaccines, describe challenges associated with producing influenza vaccine antigens, and discuss the inherent difficulties of updating influenza vaccine strains each influenza season. We argue that seasonal influenza vaccines can be dramatically improved by modernizing antigen production processes and developing models that are better at predicting viral evolution. Resources should be specifically dedicated to improving seasonal influenza vaccines while developing entirely new vaccine platforms.

摘要

季节性流感疫苗可预防与流感相关的疾病、住院和死亡。然而,这些疫苗的效果不如其他病毒性疫苗,显然还有改进的空间。在这里,我们回顾了季节性流感疫苗的历史,描述了生产流感疫苗抗原所面临的挑战,并讨论了每个流感季节更新流感疫苗株的固有困难。我们认为,通过使抗原生产过程现代化和开发更能预测病毒进化的模型,可以大大改善季节性流感疫苗。在开发全新疫苗平台的同时,应专门投入资源来改进季节性流感疫苗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a44d/7529958/f8a1e6b46619/nihms-1603441-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a44d/7529958/06f5d658b96a/nihms-1603441-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a44d/7529958/f8a1e6b46619/nihms-1603441-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a44d/7529958/06f5d658b96a/nihms-1603441-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a44d/7529958/f8a1e6b46619/nihms-1603441-f0002.jpg

相似文献

1
Challenges of Making Effective Influenza Vaccines.制作有效流感疫苗的挑战。
Annu Rev Virol. 2020 Sep 29;7(1):495-512. doi: 10.1146/annurev-virology-010320-044746. Epub 2020 May 11.
2
The evolution of seasonal influenza viruses.季节性流感病毒的演变。
Nat Rev Microbiol. 2018 Jan;16(1):47-60. doi: 10.1038/nrmicro.2017.118. Epub 2017 Oct 30.
3
Challenges of selecting seasonal influenza vaccine strains for humans with diverse pre-exposure histories.为具有不同暴露前病史的人群选择季节性流感疫苗毒株的挑战。
Curr Opin Virol. 2014 Oct;8:85-9. doi: 10.1016/j.coviro.2014.07.007. Epub 2014 Aug 11.
4
Generation of DelNS1 Influenza Viruses: a Strategy for Optimizing Live Attenuated Influenza Vaccines.生成 DelNS1 流感病毒:优化活流感疫苗的策略。
mBio. 2019 Sep 17;10(5):e02180-19. doi: 10.1128/mBio.02180-19.
5
Influenza Virus: Dealing with a Drifting and Shifting Pathogen.流感病毒:应对一种不断漂移和变异的病原体。
Viral Immunol. 2018 Mar;31(2):174-183. doi: 10.1089/vim.2017.0141. Epub 2018 Jan 26.
6
Influenza vaccines: a moving interdisciplinary field.流感疫苗:一个不断发展的跨学科领域。
Viruses. 2014 Oct 9;6(10):3809-26. doi: 10.3390/v6103809.
7
Improving influenza vaccine virus selection: report of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14-16 June 2010.改进流感疫苗病毒选择:世卫组织于 2010 年 6 月 14 日至 16 日在瑞士日内瓦世卫组织总部举行的一次世卫组织非正式磋商的报告。
Influenza Other Respir Viruses. 2012 Mar;6(2):142-52, e1-5. doi: 10.1111/j.1750-2659.2011.00277.x. Epub 2011 Aug 8.
8
A Perspective on Nanoparticle Universal Influenza Vaccines.纳米颗粒通用流感疫苗的前景
ACS Infect Dis. 2018 Dec 14;4(12):1656-1665. doi: 10.1021/acsinfecdis.8b00206. Epub 2018 Nov 15.
9
Production of live attenuated influenza vaccines against seasonal and potential pandemic influenza viruses.生产针对季节性和潜在大流行性流感病毒的减毒活流感疫苗。
Curr Opin Virol. 2014 Jun;6:34-9. doi: 10.1016/j.coviro.2014.02.008. Epub 2014 Apr 3.
10
Development of an Alternative Modified Live Influenza B Virus Vaccine.一种替代的乙型流感病毒减毒活疫苗的研发。
J Virol. 2017 May 26;91(12). doi: 10.1128/JVI.00056-17. Print 2017 Jun 15.

引用本文的文献

1
Epitope-Specific Antibody Immunodominance Driving Antibody and Influenza Viral Evolution During 2010- 2024.2010年至2024年期间,表位特异性抗体免疫优势驱动抗体和流感病毒进化。
Open Forum Infect Dis. 2025 Jul 25;12(8):ofaf440. doi: 10.1093/ofid/ofaf440. eCollection 2025 Aug.
2
Hybrid peptide DNA nanomaterials enable potent and broad-spectrum virus neutralization.杂合肽DNA纳米材料可实现高效广谱的病毒中和作用。
bioRxiv. 2025 Jul 25:2025.07.21.666049. doi: 10.1101/2025.07.21.666049.
3
Epitope Variation in Hemagglutinin and Antibody Responses to Successive A/Victoria A(H1N1) Strains in Young and Older Adults Following Seasonal Influenza Vaccination: A Pilot Study.

本文引用的文献

1
Earliest infections predict the age distribution of seasonal influenza A cases.早期感染可预测季节性甲型流感病例的年龄分布。
Elife. 2020 Jul 7;9:e50060. doi: 10.7554/eLife.50060.
2
Influenza Vaccines Delivered in Early Childhood Could Turn Antigenic Sin into Antigenic Blessings.婴幼儿期接种流感疫苗可能会使抗原性错误变成抗原性祝福。
Cold Spring Harb Perspect Med. 2020 Oct 1;10(10):a038471. doi: 10.1101/cshperspect.a038471.
3
Comparative Immunogenicity of Several Enhanced Influenza Vaccine Options for Older Adults: A Randomized, Controlled Trial.
季节性流感疫苗接种后年轻人和老年人中血凝素表位变异及对连续A/维多利亚A(H1N1)毒株的抗体反应:一项初步研究
Vaccines (Basel). 2025 Jul 21;13(7):774. doi: 10.3390/vaccines13070774.
4
Influenza Vaccine Effectiveness in Australia During 2017-2019.2017 - 2019年澳大利亚流感疫苗的有效性
Influenza Other Respir Viruses. 2025 Jul;19(7):e70137. doi: 10.1111/irv.70137.
5
A live attenuated NS1-deficient vaccine candidate for cattle-origin influenza A (H5N1) clade 2.3.4.4.b viruses.一种针对牛源甲型流感(H5N1)2.3.4.4.b分支病毒的减毒活NS1缺陷候选疫苗。
NPJ Vaccines. 2025 Jul 12;10(1):151. doi: 10.1038/s41541-025-01207-9.
6
mRNA Vaccine Technology Beyond COVID-19.新冠疫情之后的mRNA疫苗技术
Vaccines (Basel). 2025 May 31;13(6):601. doi: 10.3390/vaccines13060601.
7
H3 hemagglutinin proteins optimized for 2018 to 2022 elicit neutralizing antibodies across panels of modern influenza A(H3N2) viruses.针对2018年至2022年优化的H3血凝素蛋白可引发针对多种现代甲型H3N2流感病毒的中和抗体。
J Immunol. 2025 Jul 1;214(7):1698-1713. doi: 10.1093/jimmun/vkaf092.
8
Spatiotemporal control of immune responses with nucleic acid cocktail vaccine.核酸混合疫苗对免疫反应的时空控制
Adv Ther (Weinh). 2024 Nov;7(11). doi: 10.1002/adtp.202400263. Epub 2024 Sep 6.
9
Antigenic drift expands influenza viral escape pathways from recalled humoral immunity.抗原漂移扩展了流感病毒逃避回忆性体液免疫的途径。
Immunity. 2025 Mar 11;58(3):716-727.e6. doi: 10.1016/j.immuni.2025.02.006. Epub 2025 Feb 28.
10
Proteolysis-targeting influenza vaccine strains induce broad-spectrum immunity and in vivo protection.蛋白酶靶向流感疫苗株可诱导广谱免疫和体内保护。
Nat Microbiol. 2025 Feb;10(2):431-447. doi: 10.1038/s41564-024-01908-2. Epub 2025 Jan 15.
几种增强型流感疫苗在老年人中的免疫原性比较:一项随机对照试验。
Clin Infect Dis. 2020 Oct 23;71(7):1704-1714. doi: 10.1093/cid/ciz1034.
4
Quantification of the total neuraminidase content of recent commercially-available influenza vaccines: Introducing a neuraminidase titration reagent.定量测定近期市售流感疫苗中的总神经氨酸酶含量:介绍一种神经氨酸酶滴定试剂。
Vaccine. 2020 Jan 22;38(4):715-718. doi: 10.1016/j.vaccine.2019.11.041. Epub 2019 Dec 7.
5
Influenza B Viruses Exhibit Lower Within-Host Diversity than Influenza A Viruses in Human Hosts.乙型流感病毒在人类宿主中的体内多样性低于甲型流感病毒。
J Virol. 2020 Feb 14;94(5). doi: 10.1128/JVI.01710-19.
6
Low 2018/19 vaccine effectiveness against influenza A(H3N2) among 15-64-year-olds in Europe: exploration by birth cohort.2018/19 年欧洲 15-64 岁人群中针对甲型流感病毒(H3N2)的低疫苗有效性:按出生队列探索。
Euro Surveill. 2019 Nov;24(48). doi: 10.2807/1560-7917.ES.2019.24.48.1900604.
7
Paradoxical clade- and age-specific vaccine effectiveness during the 2018/19 influenza A(H3N2) epidemic in Canada: potential imprint-regulated effect of vaccine (I-REV).2018/19 年加拿大甲型流感(H3N2)疫情期间具有矛盾的进化枝和年龄特异性的疫苗效力:疫苗(I-REV)的潜在印迹调节效应。
Euro Surveill. 2019 Nov;24(46). doi: 10.2807/1560-7917.ES.2019.24.46.1900585.
8
Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial.嵌合血凝素为基础的通用流感病毒疫苗候选物的免疫原性:一项随机、安慰剂对照、1 期临床试验的中期结果。
Lancet Infect Dis. 2020 Jan;20(1):80-91. doi: 10.1016/S1473-3099(19)30393-7. Epub 2019 Oct 17.
9
Comparison of Human H3N2 Antibody Responses Elicited by Egg-Based, Cell-Based, and Recombinant Protein-Based Influenza Vaccines During the 2017-2018 Season.2017-2018 年度流感季节中,基于鸡蛋、细胞和重组蛋白的流感疫苗诱导的人体 H3N2 抗体反应比较。
Clin Infect Dis. 2020 Sep 12;71(6):1447-1453. doi: 10.1093/cid/ciz996.
10
The neuraminidase of A(H3N2) influenza viruses circulating since 2016 is antigenically distinct from the A/Hong Kong/4801/2014 vaccine strain.自 2016 年以来流行的 A(H3N2) 流感病毒的神经氨酸酶与 A/香港/4801/2014 疫苗株在抗原性上有明显差异。
Nat Microbiol. 2019 Dec;4(12):2216-2225. doi: 10.1038/s41564-019-0522-6. Epub 2019 Aug 12.